Entrada Therapeutics (TRDA) Competitors $5.80 -0.39 (-6.23%) As of 12:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRDA vs. KURA, XNCR, MRVI, CRMD, AVBP, PHAT, PVLA, ABUS, VIR, and DNAShould you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Kura Oncology (KURA), Xencor (XNCR), Maravai LifeSciences (MRVI), CorMedix (CRMD), ArriVent BioPharma (AVBP), Phathom Pharmaceuticals (PHAT), Palvella Therapeutics (PVLA), Arbutus Biopharma (ABUS), Vir Biotechnology (VIR), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry. Entrada Therapeutics vs. Its Competitors Kura Oncology Xencor Maravai LifeSciences CorMedix ArriVent BioPharma Phathom Pharmaceuticals Palvella Therapeutics Arbutus Biopharma Vir Biotechnology Ginkgo Bioworks Kura Oncology (NASDAQ:KURA) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation. Do insiders & institutionals believe in KURA or TRDA? 86.4% of Entrada Therapeutics shares are owned by institutional investors. 6.4% of Kura Oncology shares are owned by insiders. Comparatively, 8.1% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is KURA or TRDA more profitable? Kura Oncology has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -92.30%. Entrada Therapeutics' return on equity of -17.81% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -52.32% -29.59% Entrada Therapeutics -92.30%-17.81%-14.55% Which has stronger valuation & earnings, KURA or TRDA? Entrada Therapeutics has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura Oncology$53.88M16.04-$173.98M-$2.26-4.40Entrada Therapeutics$210.78M1.05$65.63M-$1.78-3.26 Which has more risk & volatility, KURA or TRDA? Kura Oncology has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Does the media refer more to KURA or TRDA? In the previous week, Kura Oncology had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 1 mentions for Kura Oncology and 0 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.83 beat Kura Oncology's score of 0.30 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Kura Oncology Neutral Entrada Therapeutics Positive Do analysts prefer KURA or TRDA? Kura Oncology presently has a consensus target price of $24.67, indicating a potential upside of 147.78%. Entrada Therapeutics has a consensus target price of $25.67, indicating a potential upside of 342.91%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than Kura Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 2 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.63Entrada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 SummaryEntrada Therapeutics beats Kura Oncology on 11 of the 16 factors compared between the two stocks. Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRDA vs. The Competition Export to ExcelMetricEntrada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$220.44M$3.41B$6.09B$10.48BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-3.2622.5584.2227.04Price / Sales1.05478.89606.15130.16Price / Cash3.9046.9737.8662.13Price / Book0.5110.4412.306.56Net Income$65.63M-$52.47M$3.32B$276.88M7 Day Performance-4.84%1.65%0.42%0.68%1 Month Performance13.85%13.79%7.68%3.85%1 Year Performance-67.13%12.10%71.71%34.63% Entrada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRDAEntrada Therapeutics3.2525 of 5 stars$5.80-6.2%$25.67+342.9%-65.0%$220.44M$210.78M-3.26110KURAKura Oncology4.1424 of 5 stars$9.72-2.1%$24.67+153.7%-44.6%$843.78M$53.88M-4.30130Gap DownXNCRXencor3.7307 of 5 stars$11.67-16.4%$24.22+107.6%-30.5%$833.73M$110.49M-4.87280Analyst ForecastMRVIMaravai LifeSciences3.7783 of 5 stars$3.24-2.0%$5.22+61.3%-57.8%$826.09M$259.18M-2.38610News CoverageAnalyst ForecastOptions VolumeGap DownCRMDCorMedix3.3699 of 5 stars$10.55-0.2%$18.00+70.6%-3.5%$822.60M$43.47M14.0530AVBPArriVent BioPharma1.5447 of 5 stars$20.19-3.4%$39.14+93.9%-34.0%$822.15MN/A-5.0440PHATPhathom Pharmaceuticals2.982 of 5 stars$11.57-7.7%$17.50+51.3%-19.2%$818.51M$55.25M-2.44110PVLAPalvella Therapeutics1.7575 of 5 stars$73.89-3.1%$75.50+2.2%N/A$817.22M$42.81M-6.11N/AShort Interest ↑ABUSArbutus Biopharma1.8347 of 5 stars$4.21-1.8%$5.00+18.9%+7.4%$806.29M$6.17M-14.5090News CoverageVIRVir Biotechnology3.5317 of 5 stars$5.74-2.1%$17.30+201.7%-26.3%$800.87M$74.21M-1.44580Analyst ForecastInsider TradeDNAGinkgo Bioworks1.2358 of 5 stars$13.47+2.4%$9.00-33.2%+82.4%$797.42M$230.82M-2.30640 Related Companies and Tools Related Companies Kura Oncology Alternatives Xencor Alternatives Maravai LifeSciences Alternatives CorMedix Alternatives ArriVent BioPharma Alternatives Phathom Pharmaceuticals Alternatives Palvella Therapeutics Alternatives Arbutus Biopharma Alternatives Vir Biotechnology Alternatives Ginkgo Bioworks Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRDA) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
